scholarly journals Assessment of risk factors for inappropriate empiric antibiotic therapy in patients with Gram-negative sterile site infection complicated by sepsis or septic shock

2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S284-S284
Author(s):  
Scott Micek ◽  
Nicholas Hampton ◽  
Marin Kollef
2017 ◽  
Vol 4 (suppl_1) ◽  
pp. S13-S14
Author(s):  
Sameer S Kadri ◽  
Yi Ling Lai ◽  
Emily Ricotta ◽  
Jeffrey Strich ◽  
Ahmed Babiker ◽  
...  

Abstract Background Discordance between in vitro susceptibility and empiric antibiotic therapy is inextricably linked to antibiotic resistance and decreased survival in bloodstream infections (BSI). However, its prevalence, patient- and hospital-level risk factors, and impact on outcome in a large cohort and across different pathogens remain unclear. Methods We examined in vitro susceptibility interpretations for bacterial BSI and corresponding antibiotic therapy among inpatient encounters across 156 hospitals from 2000 to 2014 in the Cerner Healthfacts database. Discordance was defined as nonsusceptibility to initial therapy administered from 2 days before pathogen isolation to 1 day before final susceptibility reporting. Discordance prevalence was compared across taxa; risk factors and its association with in-hospital mortality were evaluated by logistic regression. Adjusted odds ratios (aOR) were estimated for pathogen-, patient- and facility-level factors. Results Of 33,161 unique encounters with BSIs, 4,219 (13%) at 123 hospitals met criteria for discordant antibiotic therapy, ranging from 3% for pneumococci to 55% for E. faecium. Discordance was higher in recent years (2010–2014 vs. 2005–2009) and was associated with older age, lower baseline SOFA score, urinary (vs. abdominal) source and hospital-onset BSI, as well as ≥500-bed, Midwestern, non-teaching, and rural hospitals. Discordant antibiotic therapy increased the risk of death [aOR = 1.3 [95% CI 1.1–1.4]). Among Gram-negative taxa, discordant therapy increased risk of mortality associated with Enterobacteriaceae (aOR = 1.3 [1.0–1.6]) and non-fermenters (aOR = 1.7 [1.1–2.5]). Among Gram-positive taxa, risk of mortality from discordant therapy was significantly higher for S. aureus (aOR = 1.3 [1.1–1.6]) but unchanged for streptococcal or enterococcal BSIs. Conclusion The prevalence of discordant antibiotic therapy displayed extensive taxon-level variability and was associated with patient and institutional factors. Discordance detrimentally impacted survival in Gram-negative and S. aureus BSIs. Understanding reasons behind observed differences in discordance risk and their impact on outcomes could inform stewardship efforts and guidelines for empiric therapy in sepsis. Disclosures All authors: No reported disclosures.


PLoS ONE ◽  
2021 ◽  
Vol 16 (3) ◽  
pp. e0248817
Author(s):  
Anthony D. Bai ◽  
Neal Irfan ◽  
Cheryl Main ◽  
Philippe El-Helou ◽  
Dominik Mertz

Background It is unclear if a local audit would be useful in providing guidance on how to improve local practice of empiric antibiotic therapy. We performed an audit of antibiotic therapy in bacteremia to evaluate the proportion and risk factors for inadequate empiric antibiotic coverage. Methods This retrospective cohort study included patients with positive blood cultures across 3 hospitals in Hamilton, Ontario, Canada during October of 2019. Antibiotic therapy was considered empiric if it was administered within 24 hours after blood culture collection. Adequate coverage was defined as when the isolate from blood culture was tested to be susceptible to the empiric antibiotic. A multivariable logistic regression model was used to predict inadequate empiric coverage. Diagnostic accuracy of a clinical pathway based on patient risk factors was compared to clinician’s decision in predicting which bacteria to empirically cover. Results Of 201 bacteremia cases, empiric coverage was inadequate in 56 (27.9%) cases. Risk factors for inadequate empiric coverage included unknown source at initiation of antibiotic therapy (adjusted odds ratio (aOR) of 2.76 95% CI 1.27–6.01, P = 0.010) and prior antibiotic therapy within 90 days (aOR of 2.46 95% CI 1.30–4.74, P = 0.006). A clinical pathway that considered community-associated infection as low risk for Pseudomonas was better at ruling out Pseudomonas bacteremia with a negative likelihood ratio of 0.17 (95% CI 0.03–1.10) compared to clinician’s decision with negative likelihood ratio of 0.34 (95% CI 0.10–1.22). Conclusions An audit of antibiotic therapy in bacteremia is feasible and may provide useful feedback on how to locally improve empiric antibiotic therapy.


2020 ◽  
Vol 48 (12) ◽  
pp. e1370-e1371 ◽  
Author(s):  
Ruben D. Villanueva ◽  
Joseph A. Iovine ◽  
Scott G. Blair ◽  
Ryan O. Kennedy ◽  
Jasmeet S. Paul

2016 ◽  
Vol 17 (2) ◽  
pp. 210-216 ◽  
Author(s):  
Taku Oshima ◽  
Yoshiyuki Kodama ◽  
Waka Takahashi ◽  
Yosuke Hayashi ◽  
Shinya Iwase ◽  
...  

Infection ◽  
2006 ◽  
Vol 34 (1) ◽  
pp. 9-16 ◽  
Author(s):  
F. Franzetti ◽  
A. Grassini ◽  
M. Piazza ◽  
M. Degl’Innocenti ◽  
A. Bandera ◽  
...  

Author(s):  
Stefano Busani ◽  
Erika Roat ◽  
Giulia Serafini ◽  
Elena Mantovani ◽  
Emanuela Biagioni ◽  
...  

Patients with septic shock by multidrug resistant microorganisms (MDR) are a specific sepsis population with a high mortality risk. The exposure to an initial inappropriate empiric antibiotic therapy has been considered responsible for the increased mortality, although other factors such as immune-paralysis seem to play a pivotal role. Therefore, beyond conventional early antibiotic therapy and fluid resuscitation, this population may benefit from the use of alternative strategies aimed at supporting the immune system. In this review we present an overview of the relationship between MDR infections and immune response and focus on the rationale and the clinical data available on the possible adjunctive immunotherapies, including blood purification techniques and different pharmacological approaches.


Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 4623-4623
Author(s):  
Purnima Sravanti Teegavarapu ◽  
Mamta Puppala ◽  
Sai Ravi Pingali ◽  
Asmita Patel ◽  
Ibrahim Ibrahim ◽  
...  

Abstract Background: The success of anti-cancer therapies continues to be threatened by formidable nosocomial infections caused by multi-drug resistant bacteria (MDR) which effectively "escape" the effects of anti-bacterial armory. The deluge of anti-bacterial resistance among gram positive and gram negative organisms poses a major challenge to all cancer care providers. The most concerning of MDR pathogens were first described by Rice and are known as the ESKAPE pathogens (Enterococcus fecalis, Methicillin resistant staphylococcus aureus, Klebsiella pneumonia, Aceinotobacter baumnii, Pseudomonas aerogenosa and enterobacter species) which represent the paradigms of pathogenesis, transmission and resistance. Herein, we present the epidemiology, risk factors and outcomes of ESKAPE infections in patients with hematological malignancies. Methods: We conducted a retrospective review of clinical records of all patients with hematological malignancies seen at our institution. All episodes of infections with ESKAPE organisms were included. Data collected at baseline included demographics such as age, gender, comorbidities (DM/CHF/CKD/CLD), prior antibiotic therapy or hospitalization, use of empiric antibiotic therapy and presence or absence of catheter. Results: Table 1. AML ALL CLL CML MDS Age (Median) 62 49 77 73 75 Gender (M:F) 1 1.05 1.07 0.62 0.78 Type of ESKAPE (most common) Staph Staph Staph Staph Staph Median Length of stay (days) 15 11 7 9 8 All-cause mortality 37.2% 27% 14.9% 24.5% 25.2% Baseline characteristics, most common type of ESKAPE organisms along with length of stay are summarized in Table 1. Most common underlying comorbidities noted were DM (4.8%), CKD (37.7%) and CHF (49.2%). The overall rate of septic shock was 20.7%. Of the 5585 patients with AML (13.8%), ALL (6.28%), CLL (6.94%), MDS (8.58%), 516 patients (9.23%) were noted to effected with ESKAPE organisms. All-cause mortality rates are shown in (Figure 1). Discussion: The impact of ESKAPE pathogens in hematological malignancies is still very limited with few studies so far and our retrospective analysis provides an account of ESKAPE infections in a large subset of patients with hematological malignancies. ESKAPE pathogens in our study accounted for 9.23% of infections. Despite a shift from Gram positive to Gram negative reported, our study showed a predominance of gram positive organisms. High rates of septic shock and early mortality are a growing concern with the ESKAPE bugs and all-cause mortality was shown to be significantly reduced by control of air quality, barrier isolation along with prophylactic use of antibiotics in a meta-analysis of infection control interventions among patients with acute leukemia and stem cell transplantation. Limited therapeutic options for ESKAPE pathogens along with a dearth of new effective drugs with novel mechanism of action calls for exigent therapeutic interventions to reduce their incidence. Cautious use of available antibiotics along with hand hygiene, screening of patients carrying resistant strains, isolation, decolonization and careful environmental cleaning should be emphasized to strategically control the ESKAPE bugs. Our study may be limited by residual confounding and institution specific variables given that it is a single center study and may not represent the general epidemiological patterns. Figure 1. Figure 1. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document